Xpert MTB/RIF Ultra for Tuberculosis Testing in Children: A Mini-Review and Commentary

Area of Science:

• Pediatric infectious diseases
• Microbiology
• Diagnostic technology

Background:

• Childhood tuberculosis (TB) is a major cause of mortality, often underdiagnosed due to difficult and varied presentations.
• Paucibacillary disease and specimen collection challenges hinder timely diagnosis and treatment in children, contributing to high mortality rates.
• The WHO End-TB strategy emphasizes the need for sensitive and rapid diagnostic tools for pediatric TB.

Purpose of the Study:

• To review the evidence for the performance of the Xpert MTB/Rif Ultra assay in diagnosing TB in children.
• To evaluate studies in adults with paucibacillary disease relevant to pediatric TB diagnosis.
• To explore future applications of the Ultra assay, including its use with alternative specimens for pediatric TB.

Main Methods:

• Review of published clinical studies on the Xpert MTB/Rif Ultra assay's performance.
• Inclusion of studies involving both pediatric and adult populations with paucibacillary disease.
• Analysis of diagnostic sensitivity and specificity data for Ultra compared to previous assays.

Main Results:

• The Xpert MTB/Rif Ultra assay demonstrates increased analytical sensitivity compared to the Xpert MTB/Rif assay.
• Clinical studies, including those with pediatric samples, support the enhanced performance of Ultra.
• Evidence suggests Ultra's potential utility in diagnosing paucibacillary TB, relevant for pediatric cases.

Conclusions:

• The Xpert MTB/Rif Ultra assay represents a significant advancement in the rapid diagnosis of childhood TB.
• Further research into utilizing Ultra with alternative specimens could improve diagnostic yield in children.
• Implementing Ultra into diagnostic algorithms is vital for improving outcomes and achieving the End-TB goals.